Suppr超能文献

澳大利亚献血者丙型肝炎和人类免疫缺陷病毒-1 RNA 的核酸技术筛查:两种高通量检测策略的比较

Nucleic acid technology screening of Australian blood donors for hepatitis C and human immunodeficiency virus-1 RNA: comparison of two high-throughput testing strategies.

作者信息

Mison L, Seed C R, Margaritis A R, Hyland C

机构信息

Australian Red Cross Blood Service, Brisbane, Australia Australian Red Cross Blood Service, Perth, Australia.

出版信息

Vox Sang. 2003 Jan;84(1):11-9. doi: 10.1046/j.1423-0410.2003.00246.x.

Abstract

BACKGROUND AND OBJECTIVES

The aim of this study was to compare the performance of two high-throughput strategies for hepatitis C virus (HCV) and human immunodeficiency virus-1 (HIV-1) RNA nucleic acid technology (NAT) screening in a volunteer blood-donor population.

MATERIALS AND METHODS

The semiautomated Chiron Procleix HIV-1/HCV transcription mediated amplification (TMA) assay was used to screen 1 439 765 donations in two different testing configurations. Three sites (termed PDT sites) performed a mixture of individual donation (ID) and minipool (MP) testing, where 1 113 288 donations were screened as pools of 24 and an additional 32 003 donations were screened in ID format. A further two sites (termed SDT sites) screened 294 474 donations exclusively in ID format.

RESULTS

A significantly higher proportion of initial NAT reactives that failed to react on follow-up testing [termed non-repeatably reactive (NRR)] was observed for ID testing at SDT sites than at PDT sites (0.082 vs. 0.047%: P < 0.01). Within the PDT sites, however, there was no significant difference between the NRR rate for MP or ID samples (0.037 vs. 0.047%; not significant). There was a significant difference in failed run rates between PDT and SDT sites (P < 0.01), with PDT sites having a higher run failure rate owing to non-amplification of the internal control. The PDT sites also had a significantly higher overall invalid sample rate. However, the invalid sample rate, specifically caused by known equipment failure, was significantly higher in the SDT sites, possibly attributable to greater usage (P < 0.0001). Four HCV NAT-positive/antibody-negative samples were identified in the course of the study.

CONCLUSIONS

The comparison of the performance of PDT with SDT sites identified only minor differences that did not adversely impact on the timely release of blood products. Although both ID and MP strategies showed excellent specificity, irrespective of site configuration, the significantly increased NRR rate, observed exclusively for ID testing performed at SDT sites, indicates a potential for contamination that may limit the number of samples that can optimally be processed using ID testing. The performance data for ID testing in particular should serve as a useful benchmark for evaluating candidate NAT systems that are fully automated.

摘要

背景与目的

本研究旨在比较两种高通量策略在志愿者献血人群中进行丙型肝炎病毒(HCV)和人类免疫缺陷病毒1型(HIV-1)RNA核酸技术(NAT)筛查的性能。

材料与方法

采用半自动Chiron Procleix HIV-1/HCV转录介导扩增(TMA)检测法,以两种不同的检测模式对1439765份献血样本进行筛查。三个站点(称为PDT站点)采用个体献血(ID)检测和小混合池(MP)检测相结合的方式,其中1113288份样本以24人一组的混合池形式进行筛查,另外32003份样本以ID形式进行筛查。另外两个站点(称为SDT站点)仅以ID形式筛查了294474份样本。

结果

与PDT站点相比,SDT站点ID检测中初始NAT反应性但后续检测未反应的比例[称为非重复性反应性(NRR)]显著更高(0.082%对0.047%:P<0.01)。然而,在PDT站点内,MP或ID样本的NRR率之间没有显著差异(0.037%对0.047%;无显著性)。PDT站点和SDT站点之间的运行失败率存在显著差异(P<0.01),PDT站点由于内部对照未扩增而具有更高的运行失败率。PDT站点的总体无效样本率也显著更高。然而,由已知设备故障导致的无效样本率在SDT站点显著更高,可能归因于使用频率更高(P<0.0001)。在研究过程中鉴定出4份HCV NAT阳性/抗体阴性样本。

结论

PDT站点与SDT站点性能的比较仅发现了微小差异,这些差异对血液制品的及时发放没有不利影响。尽管ID和MP策略均显示出优异的特异性,与站点配置无关,但仅在SDT站点进行的ID检测中观察到的NRR率显著增加,表明存在污染可能性,这可能会限制使用ID检测可最佳处理的样本数量。特别是ID检测的性能数据应作为评估全自动候选NAT系统的有用基准。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验